Drug Trial Radar · NCT05106387
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 19, 2023
Primary completion
Jun 14, 2027
Study completion Feb 23, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 3, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Conditions
- Chronic Kidney Disease (CKD)
Interventions
NoninterventionalDrug
No investigational treatment will be given in this noninterventional extension study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse EventsTime frame: Up to 12 months post-kidney transplant
- Incidence of Serious Adverse EventsTime frame: Up to 12 months post-kidney transplant
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
University of California Irvine
Orange, California · Recruiting
Connie Frank Transplant Center at UCSF
San Francisco, California · Recruiting
Yale University of Medicine
New Haven, Connecticut · Completed
Comprehensive Transplant Center
Chicago, Illinois · Recruiting
John Hopkins Hospital
Baltimore, Maryland · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
New York University Langone Health
New York, New York · Recruiting
Penn Transplant Institute
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.